The International Osteoporosis Foundation (IOF)
Action for bone health is needed now more than ever, urges IOF
plus
Actualités sur Medizinische Behandlung
CARB-X FUNDS THE 3RD ROUND OF DEBIOPHARM’S TARGETED ANTIBIOTIC PROGRAM TO COMBAT RESISTANT N. GONORRHOEAE INFECTIONS
Lausanne, Switzerland / Boston, USA (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical ...
plusSeibersdorf Labor GmbH; Isotopia Molecular Imaging
Isotopia Molecular Imaging and Seibersdorf Labor GmbH Announce Production Agreement for 177Lu n.c.a.
Tel Aviv, Israel and Vienna, Austria (ots/PRNewswire) - Isotopia Molecular Imaging and Seibersdorf Labor are pleased to announce that they have entered into an agreement for the production of no-carrier-added Lutetium-177, a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for ...
plusSchweizerischer Nationalfonds / Fonds national suisse
SNSF opposes initiative to ban animal and human experimentation
Bern, 14.10.2021 (ots) - The Swiss National Science Foundation (SNSF) strives consistently and continuously to improve the quality of research. A ban on animal and human experiments would massively restrict the opportunity to gain knowledge and adversely affect Switzerland as a research hub. On 13 February 2022, the Swiss electorate will vote on the initiative to ban animal and human experiments. Acceptance of the ...
plusMicreos appoints Matt Regan as CEO of its Pharmaceutical business
The Hague, Netherlands (ots/PRNewswire) - Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new Pharmaceutical business that will be based in Switzerland. Following rapid growth, Micreos is preparing to spin-out its Pharmaceutical business into a separate company as per January 2022 to directly access the capital markets. This will help to fund pipeline development to progress its highly ...
plusNovaliq Receives EU Quality Management Certificate According To New Medical Device Regulation (MDR)
Heidelberg, Germany (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that it has implemented and applies a quality management system in accordance with Annex IX, Chapter I of the EU ...
plus
Fresenius Kabi Deutschland GmbH
Fresenius Kabi at ESPEN Virtual Congress 2021: EuroPN Study will provide new clinical data on critical care nutrition
Bad Homburg, Germany (ots/PRNewswire) - Real-world-data on the medical nutrition practice in Intensive Care Units (ICU) for critically ill patients is limited so far. To close this knowledge gap, Fresenius Kabi started EuroPN Study in 2019 in eleven European countries with around 100 participating hospitals[1]. At ...
plusDEBIOPHARM & DEXA MEDICA LAUNCH TRIPTORELIN COLLABORATION TO BRING NEW HOPE TO WOMEN WITH ENDOMETRIOSIS
Lausanne, Switzerland – Tangerang, Indonesia (ots) - Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, today announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, ...
plusNorgine B.V. celebrates 30 years of the bowel preparations used in colonoscopy to help prevent and diagnose gastrointestinal diseases, including colorectal cancer
Amsterdam (ots/PRNewswire) - NORGINE B.V. (Norgine), a leading European specialist pharmaceutical company, celebrates its 30th anniversary of continuous innovation in bowel preparations at the United European Gastroenterology (UEG) Week Virtual. Bowel preparations are used in colonoscopy to prevent and diagnose ...
plusMicreos secures EUR32 million for its endolysin-based platform as sustainable alternative to antibiotics
The Hague, The Netherlands (ots/PRNewswire) - Dutch biotechnology company Micreos announced it has secured another EUR32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria. This funding round will help Micreos accelerate its clinical ...
plusVidac Pharma Ltd Announces Wider Spectrum Authorization Of Its CTCL Phase 2 Clinical Trial
Rehovot, Israel (ots/PRNewswire) - BASED OF THE SATISFACTORY SAFETY DATA OF VIDAC VDA 1102 ON SELECTED PATIENTS VIDAC PHARMA RECEIVED AUTHORIZATION TO WIDEN THE SCOPE OF THE TRIAL TO CTCL WHOLE SPECTRUM OF CONDITIONS. "WE ARE VERY SATISFIED WITH THE RESULTS OF THE FIRST STEP WHICH ON TOP OF THE SAFETY RESULTS GRANTED TO OUR TRIAL A DOSE RANGING PROTOCOL AUTHORIZATION. ...
plusVidac Pharma Ltd.: New Chemical Entities Patent Granted
Rehovot, Israel (ots/PRNewswire) - Vidac Pharma Ltd. announces that it was granted a USA Patent for a new chemical family of compounds targeting the HK2-VDAC system developed by the company. The new compounds are hydrophilic and were developed to fit systemic use such as IV, IM and/or Per-Os use. "This is opening the way to explore possible treatment of solid tumors overexpressing HK2 such as Prostate, Pancreas and other ...
plus
Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing bumetanide in the treatment of Autism Spectrum Disorders in children and adolescents
Paris (ots/PRNewswire) - Servier and Neurochlore announce that no sign of effectiveness was observed in their two phase 3 clinical studies assessing bumetanide versus placebo in the treatment of Autism Spectrum Disorders (ASD) in children and adolescents. As a consequence, Servier and Neurochlore have decided, by ...
plusCartiHeal Announces Pivotal Study Results Demonstrate Agili-C(TM) Superiority to Microfracture and Debridement for the Treatment of Cartilage and Osteochondral Defects
Kfar Saba, Israel (ots/PRNewswire) - According to a Two-Year Randomized and Controlled Multinational IDE Study CartiHeal Ltd, developer of Agili-C(TM), a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, which was granted Breakthrough Device Designation by the FDA last ...
plusGES Acquires Aqwise in a Strategic Move to Form a Leading Global Water & Wastewater Treatment Technology Group
Tel Aviv, Israel (ots/PRNewswire) - GES CEO, Michael Dayan, explained that the Aqwise acquisition positions GES as a leading, dominant player in the Water, Industrial & Municipal Wastewater Market in Israel and worldwide GES, which operates in the desalination, water treatment and wastewater sector announced today ...
plusNorgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand
Amsterdam, Netherlands and Louisville, Ky. (ots/PRNewswire) - NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and US WorldMeds (USWM), a Kentucky-based specialty pharmaceutical company, today announced an exclusive licensing agreement by which Norgine will register and commercialise ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Cancerous tumours: how likely are they to metastasise?
Bern (ots) - A very aggressive type of cancer has provided a team of researchers supported by the Swiss National Science Foundation with an answer to the question of which tumour cells are at risk of spreading. Cancer treatment is sometimes complicated by the heterogeneity of the cells that form the tumour mass. The problem is how to identify the few cells that are capable of triggering metastases. Thanks to work carried ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Clinical research: patients and the public have their say
Bern (ots) - The Swiss National Science Foundation has been funding clinical studies on under-researched topics in medicine since 2016. In a first, it successfully involved representatives of patients and the public in evaluating applications. The aim of the SNSF's Investigator Initiated Clinical Trials (IICT) programme is to answer medical questions that are important to society but not a priority for industry. This ...
plus
Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics
Paris (ots/PRNewswire) - Servier, a global independent pharmaceutical Group, and Nymirum, a pioneer in RNA-targeted small molecules, announced today that they have entered into a strategic collaboration to identify and develop RNA-modulatory drugs for the treatment of neurological diseases. Under the collaboration ...
plusCOVID pandemic heightens a lack of confidence amongst the public about which medicines to take and how to use them
Nyon, Switzerland (ots/PRNewswire) - New campaign, Let's treat it right, launches as online searches for self-care surge globally[1], as people take more responsibility for their everyday health. Today sees the launch of Let's treat it right, a major new health education campaign designed to bridge a knowledge gap ...
plusAlmirall and MC2 Therapeutics announce completion of decentralized procedure in Europe for the topical treatment of mild to moderate psoriasis vulgaris in adults
Barcelona, Spain and Copenhagen, Denmark (ots/PRNewswire) - - The successful completion of a decentralized procedure is the final step before national marketing authorizations can be granted by the European countries - MC2 Therapeutics has granted Almirall exclusive European rights to commercialize this topical ...
plusTianjin Haihe Media Group presents the story of Zhang Boli in fighting COVID-19 with TCM
Wuhan (ots) - In September, 2020, Zhang Boli was awarded with the national honorary title, "the People's Hero," for his outstanding contribution to the country's fight against the COVID-19 pandemic. The decision was made to commend people who have made outstanding contribution in the fight, and carry forward their dedication and other noble qualities. This short ...
plusTianjin Haihe Media Group presents the story of Zhang Boli in fighting COVID-19 with TCM
Tianjin, China (ots) - In September, 2020, Zhang Boli was awarded with the national honorary title, "the People's Hero," for his outstanding contribution to the country's fight against the COVID-19 pandemic. The decision was made to commend people who have made outstanding contribution in the fight, and carry forward their dedication and other noble qualities. This ...
plus- 3
Vascudyne Announces Successful First Human Use of TRUE Vascular Graft for Hemodialysis Access
plus
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
Brussels and Castres, France (ots/PRNewswire) - Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage 2 melanoma patients European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic partnership in support of patients ...
plusPionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients
South San Francisco, Calif. and Cambridge, England (ots/PRNewswire) - - The partnership will support the progression of PY314, the first of Pionyr's Myeloid Tuning(TM) antibodies to enter the clinic - Pionyr will use Abcam's EPR20243 clone to evaluate TREM2 levels in tissue samples for potential future development ...
plusNorgine B.V. enters into exclusive distribution agreement for the commercialisation of PLENVU® in China with Beijing Podconley Pharmaceutical Technology & Development Co., Ltd.
Amsterdam (ots/PRNewswire) - NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and Beijing Podconley Pharmaceutical Technology & Development Co., Ltd. (Beijing Podconley), today announced an exclusive distribution agreement by which Beijing Podconley will commercialise Norgine's product ...
plusDEBIOPHARM AND UBIX THERAPEUTICS LAUNCH RESEARCH TO DEVELOP A NEW ANTI-CANCER MODALITY - ANTIBODY DEGRADUCER® CONJUGATES
Lausanne, Switzerland, Seoul, Republic of Korea (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company and Ubix Therapeutics (en.ubixtrx.com), a South Korea-based biotech company today announced their co-research agreement combining two novel proprietary technologies to specifically ...
plusDEBIOPHARM’S CD37 ANTIBODY DRUG CONJUGATE SHOWS PROMISING PHASE II RESULTS FOR THE TREATMENT OF B-CELL MALIGNANCIES
Lausanne, Switzerland (ots) - - Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of Non-Hodgkin’s Lymphoma (NHL), representing 30-40% of cases. Nearly half of DLBCL patients are not cured by first-line treatment, leaving a large number of patients at risk of worsening disease1 - Naratuximab ...
plusCombined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways
London and Toronto (ots/PRNewswire) - Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint ...
plus
Précédent234567891011Suivant